Depression in Older Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00643162
Recruitment Status : Completed
First Posted : March 26, 2008
Last Update Posted : March 27, 2012
Forest Laboratories
Information provided by:
Cedars-Sinai Medical Center

Brief Summary:

Depression is a common and disabling condition which represents a substantial public health concern, especially with the aging of the population in general. In fact, one to four percent of the older population has major depression. Although medication is the main treatment for depression, studies show that only 50% of patients show a significant response to treatment. The response might actually be less in older subjects, and with more adverse side effects due to changes in the metabolism of the older population as well as drug interaction. For these reasons (changes in metabolism and possible drug interactions) the starting dose of the antidepressant Lexapro will be 5mg, instead of 10mg.

To combat the incomplete response to medication, many combined and augmentation strategies have been developed. Examples of this would be an antidepressant medication plus a neuroleptic medication; or an antidepressant medication plus talk therapy. One non-medication treatment that is being considered is massage therapy. Recent data suggest that massage therapy can be useful for the treatment of depression.

This study proposes to perform a controlled trail to assess the effects of massage therapy on symptoms of depression in older subjects with major depression. All of the subjects will receive Lexapro, which is an FDA approved medication for the treatment of depression. Half of the subjects will receive Swedish massage for one hour, twice a week, and the other half will receive light touch for one hour, twice per week for eight weeks. Standardized rating scales that evaluate depression will be used to evaluate the subjects mood.

Condition or disease Intervention/treatment Phase
Depression Drug: Lexapro Behavioral: Light touch Behavioral: Massage Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 17 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Combination Lexapro and Massage for Treatment in Depression in Older Subjects
Study Start Date : June 2006
Actual Primary Completion Date : February 2010
Actual Study Completion Date : February 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Swedish Massage
Adding massage twice a week, for 8 weeks, and Lexapro in the treatment of depression.
Drug: Lexapro
5mg-10mg of lexapro, daily, for 9 weeks for all study participants.

Behavioral: Massage
Massage twice a week, for 8 weeks.

Sham Comparator: Light-Touch
Adding light touch twice a week, for 8 weeks, and Lexapro in the treatment of depression.
Drug: Lexapro
5mg-10mg of lexapro, daily, for 9 weeks for all study participants.

Behavioral: Light touch
Light touch twice a week, for 8 weeks

Primary Outcome Measures :
  1. Hamilton Depression Scale (HAM-D) [ Time Frame: 9 weeks ]

Secondary Outcome Measures :
  1. Beck Depression Inventory [ Time Frame: 9 weeks ]
  2. Hamilton Anxiety Scale (HAM-A) [ Time Frame: 9 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   60 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. > 60 years of age
  2. Unipolar major depression as defined by Structured Clinical Interaction DSM-IV (SCID)
  3. HAM-D score of > 17 (21-item scale)]]
  4. Not taking antidepressants for at least two weeks, 2 months for fluoxetine and MAOIs]]
  5. Capable of giving informed consent.

Exclusion Criteria:

  1. Unable to provide informed consent (e.g. severe cognitive impairment)
  2. Acute medical condition or exacerbation of chronic medical condition associated with significant distress (pain, protracted fevers, etc.) and requiring active medical treatment.
  3. High risk of suicide or violence as assessed by the investigator
  4. Current or past history of psychosis or bipolar disorder
  5. Use of psychotropic medication and/or psychotherapy outside of the study
  6. (Exposure to treatment of fluoxetine or MAOIs in the previous two months; chronic use of benzodiazepine and non-benzodiazepine sedatives, antipsychotics, psychostimulants, mood stabilizing agents, codeine, steroids, anti-inflammatory agents.
  7. Alternative medicine use in the preceding 30 days (e.g. acupuncture, herbs, etc.)
  8. History of intolerance to massage or contraindication to massage (e.g. skin lesions that prevent direct contact by the therapist)
  9. Diagnosis of schizophrenia, schizophreniform disorder, schizoaffective disorder, schizotypal disorder, psychotic depression or bipolar disorders;
  10. MMSE less than 22
  11. Alzheimer's Disease Assessment Scale-Cognitive Subscale ³ greater than 12
  12. Current drug or alcohol abuse or dependence or history of drug or alcohol abuse or dependence within the past 6 months
  13. Unstable medical or neurological conditions that are likely to interfere with the treatment of depression
  14. Currently on psychotropic medications including antidepressants or neuroleptics
  15. Active suicidal ideation or other safety issues determined by the clinician to not be suitable for inclusion in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00643162

United States, California
Cedars-Sinai Medical Center Department of Psychiatry and Behavioral Neurosciences
Los Angeles, California, United States, 90048
Sponsors and Collaborators
Cedars-Sinai Medical Center
Forest Laboratories
Principal Investigator: Robert Cohen, Ph.D., M.D. Cedars-Sinai Medical Center

Responsible Party: Dr. Robert Cohen, Cedars-Sinai Medical Center Department of Psychiatry and Behavioral Neurosciences Identifier: NCT00643162     History of Changes
Other Study ID Numbers: 8648
First Posted: March 26, 2008    Key Record Dates
Last Update Posted: March 27, 2012
Last Verified: March 2012

Keywords provided by Cedars-Sinai Medical Center:
Alternative Therapy

Additional relevant MeSH terms:
Depressive Disorder
Behavioral Symptoms
Mood Disorders
Mental Disorders
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Autonomic Agents
Peripheral Nervous System Agents
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents